These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial. Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666 [TBL] [Abstract][Full Text] [Related]
24. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501 [TBL] [Abstract][Full Text] [Related]
25. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624 [TBL] [Abstract][Full Text] [Related]
26. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study. Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382 [TBL] [Abstract][Full Text] [Related]
27. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial. Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311 [TBL] [Abstract][Full Text] [Related]
29. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP; Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740 [TBL] [Abstract][Full Text] [Related]
30. Randomized Controlled Trial of Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Comparison of Overall Response Rates. Amariyil A; Pathy S; Sharma A; Kumar S; Pramanik R; Bhoriwal S; Pandey RM J Gastrointest Cancer; 2024 Mar; 55(1):373-382. PubMed ID: 37702850 [TBL] [Abstract][Full Text] [Related]
31. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction]. Li YJ; Yuan P; Zhai JN; Yao YF; Tan LX; Li ZW; Zhang XY; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):684-693. PubMed ID: 39004983 [No Abstract] [Full Text] [Related]
32. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer]. Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171 [No Abstract] [Full Text] [Related]
33. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663 [TBL] [Abstract][Full Text] [Related]
34. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy. Chapman WC; Kim H; Bauer P; Makhdoom BA; Trikalinos NA; Pedersen KS; Glasgow SC; Mutch MG; Silviera ML; Roy A; Parikh PJ; Hunt SR Dis Colon Rectum; 2022 Feb; 65(2):198-206. PubMed ID: 34990423 [TBL] [Abstract][Full Text] [Related]
35. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070 [TBL] [Abstract][Full Text] [Related]
36. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368 [TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207 [TBL] [Abstract][Full Text] [Related]
38. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Xiao WW; Chen G; Gao YH; Lin JZ; Wu XJ; Luo HL; Lu ZH; Wang QX; Sun R; Cai PQ; Zhu CM; Liu M; Li JB; Wang YR; Jin Y; Wang F; Luo HT; Li CL; Pan ZZ; Xu RH Cancer Cell; 2024 Sep; 42(9):1570-1581.e4. PubMed ID: 39094560 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]